ClinicalTrials.gg
CompletedNCT02679508Updated Dec 13, 2023Results posted

Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

A Phase 4 interventional study of Vonoprazan and Lansoprazole in Erosive Esophagitis, sponsored by Takeda. Completed at 36 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.

Enrollment
8th of 10
208 · median 357
Started
2016
the only one that year
Phase 4
2 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
7 of 10
Takeda

Among the 10 studies testing vonoprazan in Esophagitis, this one is the 8th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 4, and was the 7th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Esophagitis, or all of them as a file.
02

Study summary

The purpose of this study is exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration (260 weeks: 5 years) of vonoprazan 10 mg or 20 mg in patients receiving maintenance treatment after healed erosive esophagitis (EE), and the curative effect of vonoprazan 20 mg versus lansoprazole in patients with EE.

Read the detailed description

This is a multicenter, open-label, randomized, parallel-group study to exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration of vonoprazan in maintenance treatment after healed EE, and the curative effect of vonoprazan versus lansoprazole in participants with EE.

Participants endoscopically diagnosed with EE of Los Angeles (LA) Classification Grades A to D at the start of treatment (Week 0 of the healing phase) will be randomly assigned to receive either vonoprazan 20 mg or lansoprazole 30 mg to be taken once daily for up to 8 weeks. Subjects with healed EE as confirmed endoscopically at Week 4 or 8 in the healing phase will enter the maintenance phase.

In the maintenance phase, the vonoprazan group and the lansoprazole group will be administered a starting dose of 10 mg and 15 mg, respectively, once daily up to 260 weeks.

If the principal investigator or investigator judged the effect of vonoprazan 10 mg or lansoprazole 15 mg to be insufficient as the maintenance treatment of EE, vonoprazan and lansoprazole may be increased to 20 mg and 30 mg, respectively.

The research period will consist of two subperiods: healing phase in which participants with EE will receive treatment (for 4 or 8 weeks) and maintenance phase in which participants will receive maintenance treatment (for 260 weeks), and thus, a total of up to 268 weeks. The number of visits will be a maximum of 18 visits. Planned number of research subjects, as the number of research subjects for entry to the maintenance phase, will be 130 participants in the vonoprazan group and 65 participants in the lansoprazole group.

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

Keywords

  • Esophagitis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healing Phase:

  1. Participants endoscopically diagnosed with EE of grades A to D by the LA Classification Grading System at the start of treatment (Week 0 of the healing phase)
  2. Participants with H. pylori negative
  3. Participants who, in the opinion of the principal investigator or investigator, are capable of understanding the content of the clinical research and complying with the research protocol requirements.
  4. Participants who can sign and date an form and information sheet prior to the conduction of the clinical research procedures.
  5. Male or female participants aged 20 years or older at the time of informed consent
  6. Therapeutic category: Ambulatory

    Maintenance Phase:

  7. Participants who have endoscopically confirmed EE healing* (mucous membrane disorder is not observed) at completion of the healing phase (Week 4 or 8 of the healing phase)

    * Participants who are classified as grade 0 according to severity classification of EE (See Table 9.b)

  8. Participants who have been determined to be appropriate as subjects for maintenance treatment of EE by the principal investigator or investigator

Exclusion criteria

Exclusion Criteria:

Healing Phase:

  1. Participants with concurrent peptic ulcer (except scarred stage) or Zollinger-Ellison syndrome
  2. Participants who received treatment with PPIs (including vonoprazan) within 4 weeks (Week -4 to Week 0) prior to the start of healing phase (Week 0 of the healing phase)
  3. Participants with a history of H. pylori eradication.
  4. Participants who have received surgery or treatment affecting gastroesophageal reflux (fundoplication or dilation for esophageal stenosis [excluding Schatzki's ring], etc.)
  5. Participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or Barrett's esophagus are allowed to be included.
  6. Participants with clinically apparent hepatic impairment (e.g., or ALT levels at the time of : >1.5 times the (ULN).
  7. Participants with renal impairment or renal failure [ (CCr) ˂30 mL/min, etc.]
  8. Participants with a history of or allergy for PPIs.
  9. Participants with a history of gastrectomy, gastrointestinal resection, or vagotomy
  10. Participants with a malignant tumor
  11. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant
  12. Participants with one of the diseases listed under administration in the vonoprazan or lansoprazole package insert
  13. Participants planning to take prohibited concomitant medications during the research period
  14. Participants participating in other clinical studies
  15. Participants who have been determined to be inappropriate as subjects in the study by the principal investigator or investigator

    Maintenance Phase:

  16. Participants who have taken PPIs other than the study drug or the control drug during the healing phase
  17. Participants who have been determined to be inappropriate as subjects in the study by the principal investigator or investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Vonoprazan group

    Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase

    Drug: Vonoprazan

  • Active comparator
    Lansoprazole group

    Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase

    Drug: Lansoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Malignant Alteration of Epithelial Cells

    Numbers of participants with malignant alteration of epithelial cells for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

    Time frame: Time Frame: Up to Week 268 (Week 260 in Maintenance Phase)

  2. Number of Participants With Parietal Cell Protrusion/Hyperplasia

    Numbers of participants with parietal cell protrusion/hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  3. Number of Participants With Foveolar Hyperplasia

    Numbers of participants with foveolar hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  4. Number of Participants With Enterochromaffin-like-cell Hyperplasia

    Numbers of participants with enterochromaffin-like-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  5. Number of Participants With G-cell Hyperplasia

    Numbers of participants with G-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

Secondary outcomes

  1. Percentage of Participants With Recurrence of Erosive Esophagitis (EE)

    Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades O and A to D) during the Maintenance Phase. The LA classification graded as follows- Grade O: normal mucosa; Grade A: nonconfluent mucosal breaks \<5 mm in length; Grade B: nonconfluent mucosal breaks ≥ 5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  2. Percentage of Participants Who Healed EE at the End of Healing Phase

    Percentage of participants who healed EE at the end of healing phase was reported.

    Time frame: Up to Week 8

  3. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) in Maintenance Phase

    Number of participants reporting one or more TEAEs in Maintenance Phase was reported. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: 260 weeks (Baseline, up to the end of Maintenance Phase)

  4. Number of Participants With Fundic Gland Polyp

    Numbers of participants with fundic gland polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  5. Number of Participants With Hyperplastic Polyp

    Numbers of participants with hyperplastic polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  6. Number of Participants With Cobblestone Mucosa

    Numbers of participants with cobblestone mucosa for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  7. Number of Participants With Multiple White and Flat Elevated Lesions

    Numbers of participants with multiple white and flat elevated lesions for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  8. Number of Participants With Black Spots

    Numbers of participants with black spots for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  9. Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Middle Gastric Body

    Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  10. Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Antrum

    Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  11. Number of Participants With Neutrophilic Infiltration in Greater Curvature of Middle Gastric Body

    Numbers of participants with neutrophilic infiltration in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  12. Number of Participants With Neutrophilic Infiltration in Greater Curvature of Antrum

    Numbers of participants with neutrophilic infiltration in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  13. Number of Participants With Atrophy in Greater Curvature of Middle Gastric Body

    Numbers of participants with atrophy in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  14. Number of Participants With Atrophy in Greater Curvature of Antrum

    Numbers of participants with atrophy in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  15. Number of Participants With Intestinal Metaplasia in Greater Curvature of Middle Gastric Body

    Numbers of participants with intestinal metaplasia in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  16. Number of Participants With Intestinal Metaplasia in Greater Curvature of Antrum

    Numbers of participants with intestinal metaplasia in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  17. Number of Participants With Presence of H.Pylori in Greater Curvature of Middle Gastric Body

    Numbers of participants with presence of H.pylori in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  18. Number of Participants With Presence of H.Pylori in Greater Curvature of Antrum

    Numbers of participants with presence of H.pylori in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

  19. Number of Participants With Gastric Polyp

    Numbers of participants with gastric polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported. The number analyzed is the number of participants with data available for analysis.

    Time frame: Up to Week 268 (Week 260 in Maintenance Phase)

07

Results

Posted Dec 13, 2023

Participant flow

Participants took part in the survey at 36 investigative sites in Japan, from 20 March 2016 to 5 March 2022.

Healing Phase
Participant flow — Healing Phase
MilestoneVonoprazan GroupLansoprazole Group
Started13969
Completed13768
Not completed21
Withdrew: Protocol violation11
Withdrew: Lost to follow-up10
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneVonoprazan GroupLansoprazole Group
Started13768
Completed10553
Not completed3215
Withdrew: Adverse event122
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject158
Withdrew: Other54

Outcome measures

PrimaryNumber of Participants With Malignant Alteration of Epithelial Cells

Numbers of participants with malignant alteration of epithelial cells for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

Time frame:
Time Frame: Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Malignant Alteration of Epithelial Cells
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Malignant Alteration of Epithelial Cells00
PrimaryNumber of Participants With Parietal Cell Protrusion/Hyperplasia

Numbers of participants with parietal cell protrusion/hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Parietal Cell Protrusion/Hyperplasia
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Parietal Cell Protrusion/Hyperplasia9945
PrimaryNumber of Participants With Foveolar Hyperplasia

Numbers of participants with foveolar hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Foveolar Hyperplasia
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Foveolar Hyperplasia151
PrimaryNumber of Participants With Enterochromaffin-like-cell Hyperplasia

Numbers of participants with enterochromaffin-like-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Enterochromaffin-like-cell Hyperplasia
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Enterochromaffin-like-cell Hyperplasia54
PrimaryNumber of Participants With G-cell Hyperplasia

Numbers of participants with G-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With G-cell Hyperplasia
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With G-cell Hyperplasia8740
SecondaryPercentage of Participants With Recurrence of Erosive Esophagitis (EE)

Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades O and A to D) during the Maintenance Phase. The LA classification graded as follows- Grade O: normal mucosa; Grade A: nonconfluent mucosal breaks \<5 mm in length; Grade B: nonconfluent mucosal breaks ≥ 5mm in length; Grade C: confluent mucosal breaks \<75% circumferential; Grade D: confluent mucosal breaks \>75% circumferential.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Number · Percentage of participants
Percentage of Participants With Recurrence of Erosive Esophagitis (EE)
Percentage of participantsVonoprazan GroupLansoprazole Group
Percentage of Participants With Recurrence of Erosive Esophagitis (EE)3.8 (1.1 to 9.6)11.3 (4.3 to 23.0)
SecondaryPercentage of Participants Who Healed EE at the End of Healing Phase

Percentage of participants who healed EE at the end of healing phase was reported.

Time frame:
Up to Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Who Healed EE at the End of Healing Phase
Percentage of participantsVonoprazan GroupLansoprazole Group
Percentage of Participants Who Healed EE at the End of Healing Phase1.4 (0.2 to 5.1)0.0 (0.0 to 5.2)
SecondaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) in Maintenance Phase

Number of participants reporting one or more TEAEs in Maintenance Phase was reported. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
260 weeks (Baseline, up to the end of Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) in Maintenance Phase
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) in Maintenance Phase12664
SecondaryNumber of Participants With Fundic Gland Polyp

Numbers of participants with fundic gland polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Fundic Gland Polyp
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Fundic Gland Polyp7545
SecondaryNumber of Participants With Hyperplastic Polyp

Numbers of participants with hyperplastic polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Hyperplastic Polyp
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Hyperplastic Polyp246
SecondaryNumber of Participants With Cobblestone Mucosa

Numbers of participants with cobblestone mucosa for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Cobblestone Mucosa
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Cobblestone Mucosa238
SecondaryNumber of Participants With Multiple White and Flat Elevated Lesions

Numbers of participants with multiple white and flat elevated lesions for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Multiple White and Flat Elevated Lesions
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Multiple White and Flat Elevated Lesions89
SecondaryNumber of Participants With Black Spots

Numbers of participants with black spots for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Black Spots
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Black Spots87
SecondaryNumber of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Middle Gastric Body

Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Middle Gastric Body
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Middle Gastric Body159
SecondaryNumber of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Antrum

Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Antrum
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Antrum119
SecondaryNumber of Participants With Neutrophilic Infiltration in Greater Curvature of Middle Gastric Body

Numbers of participants with neutrophilic infiltration in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Neutrophilic Infiltration in Greater Curvature of Middle Gastric Body
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Neutrophilic Infiltration in Greater Curvature of Middle Gastric Body10
SecondaryNumber of Participants With Neutrophilic Infiltration in Greater Curvature of Antrum

Numbers of participants with neutrophilic infiltration in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Neutrophilic Infiltration in Greater Curvature of Antrum
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Neutrophilic Infiltration in Greater Curvature of Antrum00
SecondaryNumber of Participants With Atrophy in Greater Curvature of Middle Gastric Body

Numbers of participants with atrophy in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Atrophy in Greater Curvature of Middle Gastric Body
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Atrophy in Greater Curvature of Middle Gastric Body00
SecondaryNumber of Participants With Atrophy in Greater Curvature of Antrum

Numbers of participants with atrophy in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Atrophy in Greater Curvature of Antrum
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Atrophy in Greater Curvature of Antrum77
SecondaryNumber of Participants With Intestinal Metaplasia in Greater Curvature of Middle Gastric Body

Numbers of participants with intestinal metaplasia in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Intestinal Metaplasia in Greater Curvature of Middle Gastric Body
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Intestinal Metaplasia in Greater Curvature of Middle Gastric Body00
SecondaryNumber of Participants With Intestinal Metaplasia in Greater Curvature of Antrum

Numbers of participants with intestinal metaplasia in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Intestinal Metaplasia in Greater Curvature of Antrum
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Intestinal Metaplasia in Greater Curvature of Antrum66
SecondaryNumber of Participants With Presence of H.Pylori in Greater Curvature of Middle Gastric Body

Numbers of participants with presence of H.pylori in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Presence of H.Pylori in Greater Curvature of Middle Gastric Body
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Presence of H.Pylori in Greater Curvature of Middle Gastric Body00
SecondaryNumber of Participants With Presence of H.Pylori in Greater Curvature of Antrum

Numbers of participants with presence of H.pylori in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Presence of H.Pylori in Greater Curvature of Antrum
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Presence of H.Pylori in Greater Curvature of Antrum00
SecondaryNumber of Participants With Gastric Polyp

Numbers of participants with gastric polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported. The number analyzed is the number of participants with data available for analysis.

Time frame:
Up to Week 268 (Week 260 in Maintenance Phase)
Reported as:
Count of participants · Participants
Number of Participants With Gastric Polyp
ParticipantsVonoprazan GroupLansoprazole Group
Number of Participants With Gastric Polyp8246

Adverse events

Collected over Up to Week 268 (Week 260 in Maintenance Phase). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan Group0/139 (0%)50/139 (36%)128/139 (92.1%)
Lansoprazole Group1/69 (1.4%)27/69 (39.1%)65/69 (94.2%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventVonoprazan GroupLansoprazole Group
CataractEye disorders3/1396/69
Large intestine polypGastrointestinal disorders5/1394/69
Inguinal herniaGastrointestinal disorders2/1392/69
OsteoarthritisMusculoskeletal and connective tissue disorders0/1392/69
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1392/69
Thrombotic cerebral infarctionNervous system disorders0/1392/69
Diverticulum intestinal haemorrhagicGastrointestinal disorders3/1390/69
Carpal tunnel syndromeNervous system disorders3/1391/69
Acute myocardial infarctionCardiac disorders1/1391/69
Angina unstableCardiac disorders0/1391/69
Most frequent other events
Showing 10 of 31
Most frequent other events
EventVonoprazan GroupLansoprazole Group
Gastric polypsGastrointestinal disorders62/13931/69
NasopharyngitisInfections and infestations49/13929/69
Gastric mucosal lesionGastrointestinal disorders30/13917/69
EczemaSkin and subcutaneous tissue disorders10/13910/69
Gastritis erosiveGastrointestinal disorders12/1399/69
HypertensionVascular disorders15/1396/69
BronchitisInfections and infestations13/1397/69
DiarrhoeaGastrointestinal disorders13/1396/69
InfluenzaInfections and infestations13/1391/69
Back painMusculoskeletal and connective tissue disorders13/1393/69

Baseline characteristics

Randomized Set: All participants who were enrolled in Healing Phase and who received at least one dose of any therapy during the study.

Age, Continuous
Age, Continuous(years)Vonoprazan GroupLansoprazole GroupTotal
Mean60.5 ± 11.9061.8 ± 12.1360.9 ± 11.97
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan GroupLansoprazole GroupTotal
Female412768
Male9842140
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Vonoprazan GroupLansoprazole GroupTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Vonoprazan GroupLansoprazole GroupTotal
Japan13969208
Height
Height(Centimeters (cm))Vonoprazan GroupLansoprazole GroupTotal
Mean164.4 ± 8.96162.7 ± 10.12163.8 ± 9.37
Weight
Weight(Kilograms (kg))Vonoprazan GroupLansoprazole GroupTotal
Mean68.55 ± 13.01165.98 ± 11.52067.70 ± 12.566
BMI (Body Mass Index)
BMI (Body Mass Index)(Kilogram (kg)/meter (m)^2)Vonoprazan GroupLansoprazole GroupTotal
Mean25.25 ± 3.73724.85 ± 3.28025.12 ± 3.589
Smoking History
Smoking History(Participants)Vonoprazan GroupLansoprazole GroupTotal
Never Smoked523183
Current Smoker25934
Ex-Smoker622991

5 further baseline measures are reported on the registry.

08

Study locations

36 sites
  • Tokatsu Tsujinaka Hospital
    Abiko, Chiba, Japan
  • Hohnodai Hospital National Center For Global Health and Medicine
    Ichikawa, Chiba, Japan
  • Red Cross Matsuyama Hospital
    Matsuyama, Ehime, Japan
  • Kawakubo Clinic
    Kama, Fukuoka, Japan
  • Hakodate Hospital
    Hakodate, Hokkaido, Japan
  • Aoyama Medical Clinic
    Kobe, Hyogo, Japan
  • Hyogo College Of Medicine
    Nishinomiya, Hyogo, Japan
  • KKR Takamatsu Hospital
    Takamatsu, Kagawa, Japan
  • Shirane Clinic
    Sendai, Miyagi, Japan
  • Tohoku University Hospital
    Sendai, Miyagi, Japan
  • Shin-Beppu Hospital
    Beppu, Oita, Japan
  • Kawasaki Medical University
    Kurashiki, Okayama, Japan
  • Shiga Hospital
    Otsu, Shiga, Japan
  • Shiga University Of Medical Science Hospital
    Otsu, Shiga, Japan
  • Shimane University Hospital
    Izumo, Shimane, Japan
  • Juntendo University Shizuoka Hospital
    Izunokuni, Shizuoka, Japan
  • Kohga Hospital
    Yaizu, Shizuoka, Japan
  • Masuyama Clinic
    Otawara, Tochigi, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo, Japan
  • Banno Clinic
    Ota-ku, Tokyo, Japan
  • Shimokitazawa Tomo Clinic
    Setagaya-ku, Tokyo, Japan
  • National Center For Global Health and Medicine
    Shinjyuku-ku, Tokyo, Japan
  • Nippon Medical School Hospital
    Shinjyuku-ku, Tokyo, Japan
  • Chihaya Hospital
    Fukuoka, Japan
  • Harada Hospital
    Fukuoka, Japan
  • Kimura Shiro Clinic
    Fukuoka, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Mori Clinic
    Fukuoka, Japan
  • Hanabata Clinic
    Kumamoto, Japan
  • Morinaga Ueno Clinic
    Kumamoto, Japan
  • Oki Hospital
    Kyoto, Japan
  • Arita Hospital
    Oita, Japan
  • Asahigaoka Hospital
    Okayama, Japan
  • Kawasaki Hospital
    Okayama, Japan
  • Matsuki Clinic
    Shizuoka, Japan
  • Oizumi Medical Clinic
    Yamagata, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Mar 2022, 71 months.

Results were first posted in Dec 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2016
First posted
Feb 10, 2016
StartActual
Mar 20, 2016
Primary completionActual
Mar 5, 2022
CompletionActual
Mar 5, 2022
Results first posted
Dec 13, 2023
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02679508
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 10, 2016
Start date
Mar 20, 2016
Primary completion
Mar 5, 2022
Completion
Mar 5, 2022
Results posted
Dec 13, 2023
Last update
Dec 13, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion